TRIX with treats: the considerable safety benefits of a transfusion medicine registry

Abstract

http://onlinelibrary.wiley.com/doi/10.1111/trf.15351/full

Proceedings of the 2022 NHLBI and OASH state of the science in transfusion medicine symposium

“…Differences include suppression of endogenous RBC production in congenital hemoglobinopathies, quality of life, or performance status such as in myelodysplastic syndromes 21 . Clinical, preclinical, and translational studies are required to define: TDM approaches to chronic transfusion; risk factors that influence RBC alloimmunization and iron overload; donor and component characteristics that influence the in vivo survival of transfused RBCs; and effects of transfusion on the genesis and clearance of native RBCs 22,23 …”

Unmasking delayed hemolytic transfusion reactions in patients with sickle‐cell disease: Challenges and opportunities for improvement

“…Massachusetts may be the first step and model for a national program, which will be necessary as many patients travel across state borders for care. There are ongoing regional efforts by multiple blood banks to create a networked antibody registry that interfaces with blood bank information systems, 40 modeled after the successful Dutch TRIX database 36 . To facilitate information sharing between different hospital networks and reference laboratories without violating HIPAA, institutional blood transfusion consent forms could be edited to include obtaining consent to share with other blood banks and healthcare providers the patient's red cell genotype/phenotype, alloantibody information, transfusion history, and hematopoietic stem cell transplantation history.…”

Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal

“…11,43 If complex alloantibody profiles were known a priori and corresponding donor databases were available, compatible donor units could be readily identified, allowing transfusion requirements to be addressed in a more timely and safe manner. 38,39,44…”